Launch of OEM self-tests in Boots
Abingdon Health PLC (AIM:ABDX) Interim Results
Interim Results for the six months ended 31 December 2023
Abingdon Health PLC (AIM:ABDX) Final Results
York, U.K. 17 October 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces its final results for the
Abingdon Health PLC (AIM:ABDX) Salistick™ to be launched in Tesco
Salistick™, the first ever saliva pregnancy test, to be launched in Tesco
Abingdon Health PLC (AIM:ABDX) Launch of Salistick™ saliva pregnancy test
Superdrug to sell Salistick™, the first ever saliva pregnancy test, initially in 400 stores and online Salistick™ also to launch on the Abingdon Simply Test website
Abingdon Health PLC (AIM:ABDX) Senzo and Abingdon Health enter into strategic partnership
Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities
Abingdon Health PLC (AIM:ABDX) AppDx ® lateral flow smartphone reader granted further patent
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its
Abingdon Health PLC (AIM:ABDX) Trading Update
York, U.K. 28 February 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), provides its half-year trading update for the six months
Abingdon Health PLC (AIM:ABDX) Award of Options under new LTIP Scheme
York, U.K. 19 December 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces the establishment of a new Long Term Incentive Plan
Abingdon Health PLC (AIM:ABDX) Preliminary Results
York, U.K. 24 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces its preliminary results for the year ended
Abingdon Health PLC (AIM:ABDX) Further re. Outcome of Judicial Review
All grounds were dismissed, including the claim of state aid, apparent bias and national preference
Abingdon Health PLC (AIM:ABDX) Outcome of Judicial Review – All claims brought by GLP dismissed
York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, notes the judgement by Mr Justice Waksman in